Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Recurrent Paenibacillus infection.

Szaniawski MA, Spivak AM.

Oxf Med Case Reports. 2019 May 31;2019(5):omz034. doi: 10.1093/omcr/omz034. eCollection 2019 May.

2.

A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation.

Reeves DB, Duke ER, Wagner TA, Palmer SE, Spivak AM, Schiffer JT.

Nat Commun. 2018 Nov 16;9(1):4811. doi: 10.1038/s41467-018-06843-5.

3.

Sex Influences SAMHD1 Activity and Susceptibility to Human Immunodeficiency Virus-1 in Primary Human Macrophages.

Szaniawski MA, Spivak AM, Bosque A, Planelles V.

J Infect Dis. 2019 Feb 15;219(5):777-785. doi: 10.1093/infdis/jiy583.

PMID:
30299483
4.

Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.

Macedo AB, Novis CL, De Assis CM, Sorensen ES, Moszczynski P, Huang SH, Ren Y, Spivak AM, Jones RB, Planelles V, Bosque A.

JCI Insight. 2018 Oct 4;3(19). pii: 122673. doi: 10.1172/jci.insight.122673.

5.

Synthetic Ingenols Maximize Protein Kinase C-Induced HIV-1 Latency Reversal.

Spivak AM, Nell RA, Petersen M, Martins L, Sebahar P, Looper RE, Planelles V.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01361-18. doi: 10.1128/AAC.01361-18. Print 2018 Nov.

6.

Influence of Biological Sex, Age, and HIV Status in an In Vitro Primary Cell Model of HIV Latency Using a CXCR4 Tropic Virus.

Macedo AB, Resop RS, Martins LJ, Szaniawski MA, Sorensen ES, Spivak AM, Nixon DF, Jones RB, Planelles V, Bosque A.

AIDS Res Hum Retroviruses. 2018 Sep;34(9):769-777. doi: 10.1089/AID.2018.0098. Epub 2018 Aug 10.

PMID:
29926732
7.

SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition.

Szaniawski MA, Spivak AM, Cox JE, Catrow JL, Hanley T, Williams ESCP, Tremblay MJ, Bosque A, Planelles V.

MBio. 2018 May 15;9(3). pii: e00819-18. doi: 10.1128/mBio.00819-18.

8.

CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.

Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu SK, Giron LB, Serra-Peinado C, Genescà M, Castellví J, Wu G, Del Rio Estrada PM, González-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, Reyes-Terán G, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ.

Sci Transl Med. 2018 Apr 18;10(437). pii: eaar6759. doi: 10.1126/scitranslmed.aar6759.

9.

Novel Latency Reversal Agents for HIV-1 Cure.

Spivak AM, Planelles V.

Annu Rev Med. 2018 Jan 29;69:421-436. doi: 10.1146/annurev-med-052716-031710. Epub 2017 Nov 3.

10.

Lues Maligna.

Johnson RA, Spivak AM.

Open Forum Infect Dis. 2017 Aug 3;4(3):ofx139. doi: 10.1093/ofid/ofx139. eCollection 2017 Summer. No abstract available.

11.

Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.

Rachakonda T, Kendall B, Spivak AM, Boltax J.

Open Forum Infect Dis. 2017 Jun 17;4(3):ofx126. doi: 10.1093/ofid/ofx126. eCollection 2017 Summer.

12.

Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation.

Bosque A, Nilson KA, Macedo AB, Spivak AM, Archin NM, Van Wagoner RM, Martins LJ, Novis CL, Szaniawski MA, Ireland CM, Margolis DM, Price DH, Planelles V.

Cell Rep. 2017 Jan 31;18(5):1324-1334. doi: 10.1016/j.celrep.2017.01.022.

13.

Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo.

Spivak AM, Larragoite ET, Coletti ML, Macedo AB, Martins LJ, Bosque A, Planelles V.

Retrovirology. 2016 Dec 20;13(1):88. doi: 10.1186/s12977-016-0319-0.

14.

HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function.

Garrido C, Spivak AM, Soriano-Sarabia N, Checkley MA, Barker E, Karn J, Planelles V, Margolis DM.

Front Immunol. 2016 Sep 21;7:356. eCollection 2016.

15.

HIV-1 Eradication: Early Trials (and Tribulations).

Spivak AM, Planelles V.

Trends Mol Med. 2016 Jan;22(1):10-27. doi: 10.1016/j.molmed.2015.11.004. Epub 2015 Dec 12. Review.

16.

BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency.

Pache L, Dutra MS, Spivak AM, Marlett JM, Murry JP, Hwang Y, Maestre AM, Manganaro L, Vamos M, Teriete P, Martins LJ, König R, Simon V, Bosque A, Fernandez-Sesma A, Cosford ND, Bushman FD, Young JA, Planelles V, Chanda SK.

Cell Host Microbe. 2015 Sep 9;18(3):345-53. doi: 10.1016/j.chom.2015.08.009.

17.

Modeling HIV-1 Latency in Primary T Cells Using a Replication-Competent Virus.

Martins LJ, Bonczkowski P, Spivak AM, De Spiegelaere W, Novis CL, DePaula-Silva AB, Malatinkova E, Trypsteen W, Bosque A, Vanderkerckhove L, Planelles V.

AIDS Res Hum Retroviruses. 2016 Feb;32(2):187-93. doi: 10.1089/aid.2015.0106. Epub 2015 Jul 14.

18.

Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.

Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V.

Antimicrob Agents Chemother. 2015 Oct;59(10):5984-91. doi: 10.1128/AAC.01077-15. Epub 2015 Jul 13.

19.

A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.

Spivak AM, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R 3rd, McCance-Katz EF, Lai J, Kennedy M, Chander G, Siliciano RF, Siliciano JD, Deeks SG.

Clin Infect Dis. 2014 Mar;58(6):883-90. doi: 10.1093/cid/cit813. Epub 2013 Dec 12.

20.

Urinary tract infections: current and emerging management strategies.

Barber AE, Norton JP, Spivak AM, Mulvey MA.

Clin Infect Dis. 2013 Sep;57(5):719-24. doi: 10.1093/cid/cit284. Epub 2013 May 3. Review.

21.

Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration.

Weil AF, Ghosh D, Zhou Y, Seiple L, McMahon MA, Spivak AM, Siliciano RF, Stivers JT.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):E448-57. doi: 10.1073/pnas.1219702110. Epub 2013 Jan 22.

22.

Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors.

Spivak AM, Salgado M, Rabi SA, O'Connell KA, Blankson JN.

J Virol. 2011 Oct;85(19):10399-403. doi: 10.1128/JVI.05409-11. Epub 2011 Jul 27.

23.

Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy.

Gaillard S, Dinoso JB, Marsh JA, DeZern AE, O'Connell KA, Spivak AM, Alwood K, Durand CM, Ambinder RF, Blankson JN.

J Clin Virol. 2011 Jul;51(3):195-8. doi: 10.1016/j.jcv.2011.04.002. Epub 2011 May 7.

24.

Spinal epidural abscess: current diagnosis and management.

Pradilla G, Nagahama Y, Spivak AM, Bydon A, Rigamonti D.

Curr Infect Dis Rep. 2010 Nov;12(6):484-91. doi: 10.1007/s11908-010-0140-1.

PMID:
21308559
25.

Short communication: dynamic constraints on the second phase compartment of HIV-infected cells.

Spivak AM, Rabi SA, McMahon MA, Shan L, Sedaghat AR, Wilke CO, Siliciano RF.

AIDS Res Hum Retroviruses. 2011 Jul;27(7):759-61. doi: 10.1089/AID.2010.0199. Epub 2011 Jan 15.

26.

Using highly active antiretroviral therapy to decrease perioperative HIV-1 transmission risk.

Spivak AM, Siliciano RF.

AIDS. 2010 Jun 19;24(10):1603-4; author reply 1604. doi: 10.1097/QAD.0b013e32832f3155. No abstract available.

27.

Seronegative HIV-1 infection: a review of the literature.

Spivak AM, Sydnor ER, Blankson JN, Gallant JE.

AIDS. 2010 Jun 19;24(10):1407-14. doi: 10.1097/QAD.0b013e32833ac65c. Review.

PMID:
20467287
28.

A case of seronegative HIV-1 infection.

Spivak AM, Brennan TP, O'Connell KA, Sydnor E, Williams TM, Siliciano RF, Gallant JE, Blankson JN.

J Infect Dis. 2010 Feb 1;201(3):341-5. doi: 10.1086/649822.

29.

A perfect storm. Gastric bezoar.

Vargas JD, Spivak AM.

Am J Med. 2009 Jun;122(6):519-21. doi: 10.1016/j.amjmed.2009.03.006. No abstract available.

PMID:
19486712
30.

Surgical management of maxillofacial uremic osteodystrophy: a case report.

Rodriguez ED, Bluebond-Langner R, Spivak AM, Eisig SB.

J Oral Maxillofac Surg. 2007 Sep;65(9):1825-9. No abstract available.

PMID:
17719406
31.

[The use of etaden in patients with peptic ulcer].

Spivak AM, Reĭngardt BK, Korneĭchuk AV, Sorokina GK.

Vrach Delo. 1988 Apr;(4):25-7. Russian. No abstract available.

PMID:
3041676
32.

[Comparative evaluation of the therapeutic effect of oxyferriscorbone in peptic ulcer].

Spivak AM, Reĭngardt VK, Galetskaia TM, Liashko NA, Litinskaia EV.

Vrach Delo. 1985 Aug;(8):56-9. Russian. No abstract available.

PMID:
4072113
33.

[Changes in the hepatobiliary system of patients with peptic ulcer and chronic gastroduodenitis].

Reĭngardt BK, Spivak AM.

Vrach Delo. 1984 Jul;(7):10-3. Russian. No abstract available.

PMID:
6475000
34.

[Combination of cholinolytics and insulin in the treatment of patients with peptic ulcer relapse].

Kushnir VE, Degtiareva II, Spivak AM, Liashko NA, Lapchinskiĭ ID.

Vrach Delo. 1983 Jul;(7):29-32. Russian. No abstract available.

PMID:
6353762
35.

[Use of dimedrol in the combined treatment of peptic ulcer patients].

Kushnir VE, Reĭngardt BK, Spivak AM.

Vrach Delo. 1983 Apr;(4):40-2. Russian. No abstract available.

PMID:
6868531
36.

[Use of rosanol in chronic cholecystoangiocholitis].

Galetskaia TM, Ivanova EA, Mironova KA, Reĭngardt BK, Spivak AM.

Vrach Delo. 1982 Apr;(4):18-20. Russian. No abstract available.

PMID:
7101849
37.

[Effectiveness of taking lidocaine per os].

Mironova KA, Ivanova EA, Galetskaia TM, Fomina AA, Spivak AM.

Vrach Delo. 1980 Dec;(12):45-8. Russian. No abstract available.

PMID:
7222579
38.

[Treatment of exacerbated peptic ulcer by pharmacological vagotomy and DOCA].

Kushnir VE, Degtiareva II, Spivak AM, Korneĭchuk AV, Liashko NA.

Vrach Delo. 1980 Jan;(1):73-7. Russian. No abstract available.

PMID:
7376591
39.

[Use of liquiriton in duodenal ulcer].

Spivak AM.

Vrach Delo. 1978 Mar;(3):84-6. Russian. No abstract available.

PMID:
645046
40.

[Use of bispan in ulcer disease].

Galetskaia TM, Mironova KA, Okhonko VI, Spivak AM, Fomina AA.

Vrach Delo. 1975 Jan;(1):15-8. Russian. No abstract available.

PMID:
237368
41.

[Use of trasycor in disorders of the cardiac rhythm and ischemic heart disease].

Fomina AA, Spivak AM, Mironova KA, Reingardt BK.

Vrach Delo. 1974 Jun;(6):46-9. Russian. No abstract available.

PMID:
4466091
42.

[Use of protein hydrolysates and anabolic steroids in the complex treatment of patients with ulcer disease].

Spivak AM.

Vrach Delo. 1973 Oct;10:3-7. Russian. No abstract available.

PMID:
4783297
43.

[Use of oxyferriscorbon in peptic ulcer].

Spivak AM, Galetskaia TM, Liashko NA, Okhonko VI.

Vrach Delo. 1973 Apr;4:19-22. Russian. No abstract available.

PMID:
4712061
44.

[Clinical evaluation of the effectiveness of Dopegyt in hypertension].

Fomina AA, Spivak AM, Mironova KA.

Vrach Delo. 1972 Jul;7:56-60. Russian. No abstract available.

PMID:
5083759
45.

[Experience in treating patients with circulatory insufficiency with acedoxin].

Reĭngardt BK, Spivak AM.

Vrach Delo. 1972 May;5:72-5. Russian. No abstract available.

PMID:
5029806
46.

[Functional state of the liver in patients with peptic ulcer during the benzohexonium therapy].

Reĭngardt BK, Spivak AM, Tsygankov AT.

Vrach Delo. 1969 Jul;7:82-5. Russian. No abstract available.

PMID:
4392432
47.

Supplemental Content

Loading ...
Support Center